Drug differences between ACE inhibitors in experimental settings and clinical practice.
In recent years, growing evidence has suggested a beneficial effect from the use of angiotensin converting enzyme (ACE) inhibitors after myocardial infarction. Since important differences between the structure and effects of the various ACE inhibitors exist, differences in outcome can be expected. This review discusses the structural, pharmacodynamic and pharmacokinetic differences between ACE inhibitors administered after myocardial infarction, both in experimental settings and in clinical practice.
Voors
A A
AA
Department of Clinical Pharmacology, University of Groningen, The Netherlands.
Kingma
J H
JH
van Gilst
W H
WH
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D012084:Renin-Angiotensin System / Q000187:drug effects* / Q000502:physiology; D013329:Structure-Activity Relationship; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors